Gen­script re­bounds on HKEX with staunch de­fense of Leg­end Biotech's CAR-T da­ta in­tegri­ty

Af­ter a scathing short re­port trig­gered a land­slide for Gen­script’s stock and forced it to halt trad­ing, the com­pa­ny has man­aged to sal­vage some of that loss with a re­sponse is­sued Fri­day morn­ing.

In the state­ment, Gen­script kicked back against the al­le­ga­tions lev­eled against Nan­jing Leg­end Biotech, its sub­sidiary de­vel­op­ing a J&J-part­nered CAR-T ther­a­py. Their Hong Kong-list­ed shares has risen al­most 16% from the low­est point Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER